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Chemo-radiotherapyAbstract Ewing’s sarcoma is a malignant tumor belonging to the group of small round cells
tumors. Histologically similar to soft tissue neoplasms originally described as primitive neuro-
ectodermal tumors (PNET), in the WHO classiﬁcation, Ewing’s sarcoma and PNET are labeled
together under the rubric of EWS/PNET. Rarely located in the nasal cavity and the para-nasal
sinuses, we report three cases of Ewing’s sarcoma of maxillary bone and sinus. Our patients, 2 males
and one female, were aged 20, 16 and 13 years respectively. The chief complaint was a painful face
swelling. The diagnosis was retained on histologic and immuno-histochemical results. In two cases,
surgery was performed as primary treatment modality followed by chemo-radiotherapy, which was
the only therapeutic modality in the remaining case. After a follow-up of 2, 3 and 8 years (for each
patient), we did not report local or distant failures.
 2016 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Contents
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of the right maxillary sinus.1. Introduction
Ewing’s sarcomas are malignant round cells neoplasms. They
are the second most common malignant bone tumor in chil-
dren after osteosarcoma.1,2 Most cases arise in the long bones
of the limbs or the pelvis. Primary location in head and neck
region is uncommon and accounts for 1–4% of all Ewing’s sar-
comas.3 Primary sino-nasal location is even rarer. The mand-
ible and the skull base are the two most common primary
sites in this particular area.2 Most sino-nasal Ewing’s sarcomas
previously described in the literature consist of sporadic case
reports that predominantly lack molecular conﬁrmation or
long-term follow-up, excepting the 14 cases reported by Hafezi
et al.4 Compared to other soft tissue and bone sites, diagnosis
is often challenging. The differential diagnosis is, in fact,
broader and includes speciﬁc tumors for this site and the other
round cells neoplasms.4 The histologic and immuno-
phenotypic diversity of Ewing’s sarcomas makes further difﬁ-
culty particularly in small biopsies. Through three cases, we
attempted to make a review of the literature to determine
clinico-pathologic features, treatment strategies and prognos-
tic factors.
2. Methods
It is a retrospective review of 3 patients followed for Ewing’s
sarcoma of maxillary bone and sinus in Salah Azaiez Institute
of Oncology. They were still alive till the date of data collec-
tion, which made the access to their medical records relatively
easy.
Diagnosis was based on histologic and immuno-histo-
chemical ﬁndings and only one patient of the three had a
molecular conﬁrmation showing the EWS-FLI1 fusion
transcript.
Local extension was assessed based on clinical and diagnos-
tic imaging ﬁndings including head and neck computed tomog-
raphy (CT) in all cases and magnetic resonance (MRI) in one
case. Distant extension evaluation was performed using tho-
racic and abdominal CT, bone marrow biopsy and bone
scintigraphy.
Tumor stage was retrospectively re-evaluated using the
American Joint Committee on Cancer (AJCC) staging manual
sixth edition.
Chemotherapy regimen was that of the Euro-EWING-99
study using six cycles VIDE (Vincristine–Ifosfamide–Doxoru-
bicin–Etoposide) as initial chemotherapy for all patients with
VAI (vincristine, dactinomycin, and ifosfamide) as continuing
chemotherapy for patients with good responses to VIDE.
Additional radiation therapy was done for all patients.
Fractionation was classic (1.8-2 GY/session; 5 days/week) with
a total dose varying between 52 and 70 Gy on the initial or the
postoperative residual tumor volume.Assessment of chemotherapy response was performed using
cervical CT after the 6 VIDE cycle. Follow-up was endoscopic
at each consultation. Additional imaging associated CT
8 weeks after the end of radiation therapy, then yearly or if
suspicious clinic and endoscopic changes. MRI was performed
in case of CT doubt on a local failure.
3. Results
3.1. Patients and clinical findings
Three patients, 2 males and 1 female were included. Ages at
presentation were 13, 16 and 20 years (mean age: 16.3 years).
Neither pathological personal history nor family history of
cancer was noted. The chief complaint was a painful face swel-
ling. Other functional complaints could be summarized as
follows:
– Spontaneous tooth mobility and exophthalmos were noted
in one case, which wandered the diagnosis before the histo-
logical results.
– General complaints were limited to weight loss reported by
one patient.
The average time to consult was 1.6 months (1–2 months)
after the onset of the functional complaints.
Apart from face swelling which was left sided in 2 cases and
right sided in 1 case, clinical examination did not reveal any
associated cervical lymphadenopathies.
3.2. Imaging and distant extension evaluation findings
Limited lesion to the anterior wall of the maxillary sinus and
its surrounded tissues was noted in one case (Fig. 1). In the
other cases, this maxillary tumor extended to:
Figure 2 MRI axial and sagittal sections: extended tumor to the left ﬂoor of the orbit, nasal fossa and cheek.
Figure 3 CT axial, coronal and sagittal sections: extension to the sphenoid and ethmoid sinuses, the left pterygo-palatine fossa and the
anterior cranial fossa.
Figure 4 CT coronal section: CT evaluation two months after
completion of treatment of the patient shown in Fig. 3: endoscopy
and biopsy were negative, despite the appearance of circumferen-
tial thickening of the surgical cavity.
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ond case (Fig. 2).
– The tumor extended farther to the sphenoid and ethmoid
sinuses, the left pterygo-palatine fossa and the anterior cra-
nial fossa in the third case (Fig. 3).
The diagnosis of Ewing’s sarcoma was based on histologi-
cal analysis of tumor specimen. This specimen was a simple
biopsy in two cases, which was done through maxillary
vestibular approach. In the last case, diagnosis was posed on
operative resected tumor, as the preoperative endoscopic
biopsy was inconclusive.
Distant extension evaluation was negative in all three cases.
Based on AJCC staging manual (sixth edition), tumor stag-
ing was T3N0M0, T3N0M0 and T4aN0M0 respectively.
4. Treatment
Two patients underwent ﬁrst-line surgery before the diagnosis
of Ewing’s sarcoma for 2 different reasons:
– In the ﬁrst case, the lesion was inaccessible to biopsy under
local anesthesia. Given its limited size, a complete excision
was accomplished through maxillary vestibular approach.
– In the second case, the biopsy evoked the diagnosis of
angio-ﬁbroma. The patient has, even, had preoperative
embolization of the left spheno-palatine artery, presumedto be the tumor-feeding artery. Extra-cranial portion of
the tumor was, then, excised via lateral nasal approach
(Moure’s technique modiﬁed by Weber-Fergusson).
Macroscopic appearance was that of a poorly deﬁned and
friable tumor. Deﬁnitive pathology report conﬁrmed the diag-
nosis of a malignant tumor showing a proliferation of
monomorphic small round cells arranged in diffuse layers
150 J. Souheil et al.and highlighted by a richly vascularized ﬁne ﬁbrous stroma.
There was a large single cell necrosis with a ﬁligree aspect.
Immunohistochemistry was positive for CD99 and anti-FLI-
1 antibodies. Cells were poorly marked by neuron speciﬁc eno-
lase (NSE). In contrast, epithelial markers: broad-spectrum
cytokeratin and epithelial membrane antigen (EMA) were neg-
ative. One of these 2 patients had a molecular conﬁrmation
showing the EWS-FLI1 fusion transcript.
The remainder of the treatment for these two patients was
chemotherapy as described above and external beam radio-
therapy on the tumor bed at a dose of 52 Gy and 70 Gy
respectively.
In the latter case, the biopsy was afﬁrmative of the diagno-
sis of Ewing sarcoma. This patient was treated by neo-
adjuvant chemotherapy followed by 64 Gy external beam radi-
ation therapy. This exclusive chemo-radiotherapy was decided
given the young age (16 years) of the patient and even the refu-
sal of the surgery by the patient and her family.
5. Clinical course and outcome
Chemotherapy and radiotherapy were well tolerated apart
from a regressive febrile neutropenia noted in two patients.
No major functional and esthetic consequences were noted
after surgery. In fact, a patient with orbital invasion at diagno-
sis has developed permanent left blindness at the end of treat-
ment. After a follow-up of 2, 3 and 8 years (for each patient),
no local or distant relapses were reported (Fig. 4).
6. Discussion
Primary bone tumors account for 5% of all child and adoles-
cent cancers, and Ewing sarcomas are the second most com-
mon primary bone tumors.5 They are more common in white
populations, and have a slight male predominance.5 About a
quarter of Ewing sarcomas arise in soft tissues rather than
bone.5 Primary Ewing sarcoma of the head and neck is uncom-
mon. This location accounts for 3.8% of cases in a large
study.6 In other studies, Bone and soft tissue Ewing sarcomas
of the head and neck have been reported to represent from 1%
to 7% of all locations3,4,7 and up to 18% in children.4,8 Pri-
mary sino-nasal location is rarer as a subgroup of these head
and neck cancers. The exact percentage is unknown as most
studies have not focused speciﬁcally on the sino-nasal region
as a particular location among head and neck Ewing
sarcomas.4,8,9
Otherwise, tumors arising in the nasal cavities and para-
nasal sinuses present with non-speciﬁc symptoms such as nasal
obstruction, rhinorrhea and epistaxis. Therefore, tumors are
locally advanced or even metastatic at the time of diagnosis10
Face swelling was the chief complaint in our cases with a rel-
atively early clinical presentation.
The histologic and immuno-phenotypic diversity of Ewing
sarcomas, including occasional keratin and neuroendocrine
marker positivity,4,11 makes the diagnosis quite challenging
particularly in small biopsies, as was reported in one of our
patients who was diagnosed as angio-ﬁbroma. Herein, we
describe the immuno-histo-chemical proﬁle and molecular
characteristics of Ewing sarcomas according to the literature
review. In fact, the immuno-histo-chemical proﬁle of
Ewing sarcomas can be summarized as follows: Pan-Cytokeratin /+, Vimentin +/, NSE /+, Synaptophysin
, CD117 /+, CD56 , CD99 +, WT-1 , Fli-1 +/.
These histological and differential diagnoses are summa-
rized in Table 1.4
The diagnosis of Ewing sarcoma becomes more compli-
cated since we know that there are different (not a single)
Ewing sarcomas (ES). Even more, close tumors to this latter
group were described and called Ewing-like sarcoma (ELS).
Three histological subtypes of ES were distinguished: conven-
tional/classic ES, PNET and the atypical variant. The ﬁrst two
can be easily recognized by microscopical examination and a
speciﬁc IHC proﬁle. However, the diagnosis of the atypical his-
tological variant, which shares some histological and IHC sim-
ilarities with ELS, requires molecular studies to retain the
diagnosis. In short, conventional ES (and PNET) subtypes
are characterized by a monotonous small round cell prolifera-
tion. The atypical variant can display large and clear cells,
which can mislead the diagnosis. The IHC study usually
reveals strong membranous CD99 and FLi1 nuclear positivity
in most of ES. An atypical morphology associated with poor
or negative CD99 expression should exclude other tumors,
especially those that belong to the ELS group. Genetic conﬁr-
mation shows reciprocal translocations between EWSR1 and a
gene of the ETS family (rarely between EWSR1 and non-ETS
gene family) members of transcription factors. A small group
of ESFT shows the FUS instead of the EWSR1 rearrangement
with a gene of the ETS family. Unfortunately, these gene
fusions are rarely found. Hence, the diagnosis of classic ES
or PNET with a common clinical and immune-phenotypic pro-
ﬁle (unlike atypical histological variants) do not require molec-
ular conﬁrmation except for inclusion in clinical trials. ELS
were recently described by studying molecular alterations in
EWSR1/FUS-negative unclassiﬁed/undifferentiated small
round cell sarcomas (SRCS). Nevertheless, the clinical features
of this emerging group of sarcoma are still somewhat unclear.
So as not to complicate this work, we invite you to consult the
article written by Isidro Machado et al.12
Even if Ewing sarcomas are considered radiation sensitive,
the proportion of patients primarily treated with radiation
alone has regularly declined over the last 30 years. This is
because of advances in reconstructive surgery and the aware-
ness of the late effects of radiation, such as second malignan-
cies and growth disturbances, particularly in head and neck
locations. Patients whose primary tumors are excised might
survive more often, although the prognostic is, also, inﬂuenced
by tumor’s site and size. Actual treatment plan for Ewing sar-
comas includes surgical excision and chemo-
radiotherapy.1,4,5,7
When the diagnosis is made on biopsy, neo-adjuvant
chemotherapy reduces tumor size and clear micro-metastases,
which are presumed to be present in 80% of cases, all locations
inclusive.4,13 Euro-EWING-99 study protocol recommends six
cycles VIDE (Vincristine-Ifosfamide-Doxorubicin-Etoposide)
as initial chemotherapy for all patients with VAI (vincristine,
dactinomycin, and ifosfamide) or VAC (vincristine, actino-
mycine D, cyclophosphamide) as continuing chemotherapy
for patients with good responses to VIDE.5 According to this
protocol, chemotherapy is repeated every three weeks (1 cycle).
In case of insufﬁcient bone marrow recovery (white blood cell
count <2.0 109/l or platelets <80 109/l), the next cycle of
chemotherapy is postponed and granulocyte-colony stimulat-
ing factor (G-CSF) is added to subsequent cycles.14 Che-
Table 1 Histological and differential diagnoses of Ewing sarcomas: particular focus on the maxillary bone and sinus location.
Histologic and immuno-histo-chemical aspects Diﬀerential diagnoses Interpretation
Nesting pattern:
– Present in many cases of Ewing sarcoma at
least focally
– Can be described as lobulation
Confusion with:
– Carcinomas: particularly in those focally
staining for keratin and synaptophysin
– Olfactory neuroblastoma (ONB)
Carcinomas are generally diﬀusely
positive for multiple keratins and rarely
occur in young patients
Cases of Ewing sarcomas with a great
degree of nesting and lack of keratin
staining raise the possibility of ONB:
– ONB: S100 positive, sustentacular net-
work, diffuse positivity for neuroen-
docrine markers and negativity for
CD99
– Ewing sarcomas: possible focal posi-
tivity for synaptophysin and other
neuro-endocrine markers
Cribriform pattern Confusion with salivary tumors The negativity for p63 ruled out salivary
tumors showing a cribriform pattern
General myogenic markers: Desmin. . .:
negatives in Ewing sarcomas
Rhabdomyosarcomas
Rhabdomyosarcoma markers: Myo D1;
Myogenin (Myf-4). . .: negatives in Ewing
sarcomas
Melanoma markers: Melanosome (HMB 45);
Melan (MART-1). . .: negatives in Ewing
sarcomas
Melanomas
Lymphoid markers: CD45 (LCA). . .: negatives
in Ewing sarcomas
Lymphomas
Neural and neuro-endocrine markers:
– Possible focal positivity for S100, synapto-
physin, NSE and chromogranin
Olfactory neuroblastoma (ONB) ONB: superior nasal cavity and
cribriform plate involvement
ONB: diﬀuse positivity for
neuroendocrine markers
Ewing sarcomas: focal staining
S100: positive in sustentacular network in
ONB and only in tumor cells in Ewing
sarcomas
Oncoproteins and tumor suppressor proteins:
– Diffuse positivity for CD99 (MIC 2) in
Ewing sarcomas
Possible (exceptional) expression in endocrine
and neuroendocrine tumors, melanoma,
chondrosarcoma, rhabdomyosarcoma,
meningeal hemangiopericytoma. . .
Cytogenetics and other molecular techniques
(FISH and RT-PCR): EWSR1-FLI1 fusion
transcript pathognomonic of Ewing sarcomas
A negative RT-PCR study possible in
Ewing sarcomas:
– Alternative fusion gene partners for
EWSR1: present in around 15% of
Ewing sarcomas in other locations
Ewing sarcomas of the Sino-nasal Tract 151motherapy is interrupted for surgery which includes wide exci-
sion of the tumor after the ﬁrst six cycles of chemotherapy.5 If
histological examination of a radically resected tumor reveal
more than 10% of viable tumor cells, radiotherapy is also
administered postoperatively.14 In this last case, considered
as poor response, the authors of Euro-EWING-99 study pro-
pose an alternative myelo-ablative high-dose chemotherapy
regimen associating Busulfan and Melphalan drugs, then res-
cue with marrow or peripheral hematopoietic stem cells.5
In case of initial surgery with a diagnosis based on deﬁnitive
histology, the same radio-chemotherapy regimen could be fol-
lowed. This chemo-radiotherapy regimen is the exclusive treat-
ment for inoperable localized tumors or in case of refusal of
surgery. Among our patients, one was treated by chemo-
radiotherapy exclusively.Other curative chemotherapy regimens have been pro-
posed. It began with single-agent cyclophosphamide, dactino-
mycin, doxorubicin, vincristine, and carmustine, followed by
single-arm multi-agent adjuvant chemotherapy trials using vin
cristine–actinomycin–cyclophosphamide (VAC) or VAC plus
doxorubicin.5 Children’s Cancer Group-Pediatric Oncology
Group (CCG-POG) cooperative study showed that ifosfamide
and etoposide (IE), alternating with the standard regimen of
vincristine, doxorubicin, cyclophosphamide (VDC), and dacti-
nomycin markedly improved both overall and event-free sur-
vival owing to a marked decrease in local (rather than
metastatic) relapse for patients with localized tumors.15 Differ-
ent approaches evolved among the European cooperative
groups. They adopted chemotherapy designs using four drugs
at once. This evolved from VACA (vincristine–doxorubicin–c
152 J. Souheil et al.yclophosphamide–actinomycin), to VAIA (substituting ifos-
famide for cyclophosphamide), to EVAIA (adding etoposide),
to the current VIDE (omitting actinomycin).5 Several trials
examined dose intensiﬁcation by either increasing doses or
decreasing the interval between these doses. Most of these tri-
als demonstrated that these regimens were more toxic but no
more effective excepting the Children’s Oncology Group
(COG) study VDC–IE treatment every 2 weeks instead of
3 weeks interval for patients with localized disease, with 14
cycles and equal cumulative doses in each group.16 This inter-
val compression provided a 25% increase in dose intensity of
all agents without an increase in toxicity. Overall and event-
free survivals were both improved in the interval-compressed
group.16
Even in cases of macroscopic complete resection, radiation
therapy, as local complementary control modality, is advo-
cated by most authors.10,17 Radiation doses range from 45 to
60 Gy. Radiotherapy is, however, associated with numerous
potentially devastating late effects that make its use problem-
atic, including ﬁbrosis, contractures, ankylosis of the
temporo-mandibular joint, facial skeleton growth disorders
and post-irradiation sarcomas, particularly in young chil-
dren.18 For some authors, proton radiotherapy is an alterna-
tive equivalent choice to photon radiotherapy for disease
control and is also well tolerated with few acute side effects
and low rates of late side effects.19
Prognosis begins with the attempt to classify patients in risk
groups. There is, in fact, no recognized risk classiﬁcation. In
the Children’s Oncology Group studies in North America,
there are three risk groups: patients with localized tumors,
patients with lung metastases only, and patients with other
or multiple metastases.5,15 The EuroEWING-99 study, cited
above, considers resectability and histological response to ini-
tial chemotherapy (for resected tumors) to assign patients to
treatments. In total, it divides the patients in six therapeutic
and prognostic groups ranging from localized resectable
tumors, lung and pleura metastatic tumors then those meta-
static outside of latter locations.5
Surprisingly, Ewing sarcomas showed a less aggressive
course in this location despite the complexity of the anatomy
of the primary site, the difﬁculty in achieving a negative-
margin resection and late presentation.4,6,7,10,17 For some
authors, initial response to chemotherapy is the only prognos-
tic factor signiﬁcantly affecting both disease free survival
(DFS) and overall survival (OS).20 Yeshvanth includes age of
the patient, stage, anatomic location and size of the tumor to
prognostic factors.14 He stated that patients younger than
15 years, with axial and sino-nasal tract disease, have a better
outcome. The ﬁve-year survival was 55% without metastases
and it was reduced to 22% with it.14 In the study of Allam
about 24 cases of head and neck Ewing’s sarcoma, the 5-
year actuarial DFS as well as OS were 30% and 53%, respec-
tively.20 OS in the Intergroup Ewing’s Sarcoma (IESS) study
was 80% at 3 years.37. Conclusion
Ewing sarcoma involves a wide histological spectrum.
Sino-nasal location is rare. A multidisciplinary management,
including surgery and chemo-radiotherapy is the only guaran-
tee of healing and longer survival. Though our study deals witha series of patients, which cannot serve for statistical analysis,
it asserts the effectiveness of EuroEWING-99 chemotherapy
regimen in association with surgery and radiotherapy. Await-
ing for more effective therapeutic targeting the EWS–FLI1
transcript expression, in particular, and inhibiting Ewing sar-
comas cell lines growth, head and neck locations (including
maxilla and sino-nasal tract) still have a better prognosis com-
pared to other locations.References
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